Rani Therapeutics Announces Research Agreement with Chugai

- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets -

SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13^th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. ("Chugai"). The full analysis confirms the RaniPill^® delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both molecules studied.

Read more at globenewswire.com